Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orexo AB's revenue for the
three
months ended in Jun. 2026 was kr3.5 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was kr130.5 Mil.
Orexo AB's Revenue per Share for the
three
months ended in Jun. 2026 was kr0.09.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr3.23.
Warning Sign:
Orexo AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Orexo AB was -31.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -66.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -52.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -24.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Orexo AB's highest 3-Year average Revenue per Share Growth Rate was 32.20% per year. The lowest was -86.90% per year. And the median was 1.30% per year.
Orexo AB (CHIX:ORXs) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Orexo AB Revenue Related Terms
Orexo AB Revenue Historical Data
* Premium members only.
The historical data trend for Orexo AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Revenue distribution charts can be found below:
* The bar in red indicates where Orexo AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr130.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (CHIX:ORXS) has a Revenue of kr130.5 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Orexo AB and its competitors.
Is Orexo AB's Revenue too high?
Orexo AB's current Revenue is kr130.5 Mil. Overall, Orexo AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Revenue compare to ZTS and UTHR?
Orexo AB's Revenue of kr130.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Orexo AB and its competitors. Orexo AB's current Revenue is kr130.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Orexo AB (CHIX:ORXS) has a current Revenue of kr130.5 Mil. The stock's GF Value™ is kr7.46, compared to a current price of kr30.95 — trading 314.9% above its estimated fair value. The current Revenue is kr130.5 Mil. Orexo AB's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Orexo AB (CHIX:ORXS), the current Revenue is kr130.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (CHIX:ORXS) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of kr30.95 is trading 314.9% above its estimated GF Value™ of kr7.46.
Key valuation signals for CHIX:ORXS:
Revenue: kr130.5 Mil
GF Value™: kr7.46 vs. price of kr30.95 (314.9% above fair value)
No single metric tells the full story. See the CHIX:ORXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
41GF Score
Get the complete analysis for CHIX:ORXS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ORXS has been successfully added to your 
